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A B S T R A C T
Zika virus (ZIKV) infection is a life-threatening tropical infection, mainly caused by mosquito bite. After a very
long period of quietness, ZIKV infections have become a problematic issue again. Previously, the virus was
limited to Africa and Asia only but later it emerged in Brazil, South America, and other parts of the world in
2015. In 2016, there are emerging new cases of sexually transmitted ZIKV infection as well. At present, there is
no proper treatment and available pronounced vaccines for the treatment of ZIKV infection. The prime focal
point of this review is not only to provide imperative epidemiological information on ZIKV infection in brief but
also the current situation of vaccines testing on animal model as well as in clinical trial phases. Currently there is
no human vaccine for this pestiferous viral infection. Therefore, prevention, proper management, and up-to-date
recommendation are crucial to mitigate the possible risk of vector and non-vector transmission of ZIKV.
1. Introduction
Zika virus (ZIKV) infection is a mosquito-borne tropical infection
that became the global public health concern in early 2016. Zika in-
fection, caused by ZIKV (genus Flavivirus) is one of the most devastating
threats of 21st century. The virus was primarily known as zoonotic
pathogen and can be transmitted by Aedes sp. mosquitoes. Zika virus
was accidentally isolated from Rhesus monkeys (Macaca mulatta) in
1947 during jungle yellow fever research in the Zika forest, Uganda,
Africa [1]. Zika virus is in the shape of enveloped and icosahedral
measuring about 50 nm in size. The virus has a non-segmented, single-
stranded, positive-sense ribonucleic acid (RNA) genome which is about
10.5–11.0 kbp in size. The viral genome produces a polyprotein with
more than 3000 amino acids and this polyprotein is then cleaved into
three structural and seven non-structural proteins (Fig. 1) [1].
Zika virus infection in human was ﬁrst reported in 1952 and it was
documented that a 10-year-old Nigerian girl who presented with ma-
laria-like fever with the absence of jaundice, had shown an elevation of
speciﬁc serum antibodies to ZIKV, which previously happened to be
exclusive for monkey species. This observation led to the detection of
ZIKV in human across the globe. The global threat of ZIKV infection has
allowed researchers to study extensively on its pathogenesis and pos-
sible serious complications. Recently, severe complications such as
Guillain-Barre syndrome (GBS) and congenital microcephaly have come
into the account following the explosive outbreaks in Brazil and Central
America since early 2015 [2]. Fever, headache, red eyes (con-
junctivitis), arthralgia, rash, and other neurological abnormalities,
particularly microcephaly are the common symptoms of this deadly
infection (Fig. 2). Despite the negligible total counts of infected people
in the beginning, a recent devastating outbreak in Brazil in last 2–3
years caused huge populace to be suspected of this infection. In view of
this, World Health Organization (WHO) declared this disease extremely
threatening and alarming [2].
Zika can be transmitted via blood through Aedes sp. mosquitoes. But
the transmission through blood is an infrequent process. There is also
possibility of ZIKV transmission from mother to the baby during preg-
nancy (Fig. 3). Apart from this, recently, the sexually transmitted ZIKV
infection has been reported worldwide. The pathogens are considered
to pass into the semen or vaginal secretion and ﬁnally transmitting
during sexual intercourse [3]. For ZIKV, it has already been proved that
the virus can be seen in semen and can be infectious and lasts for a long
time [4]. The virus might have high invasiveness due to its presence in
transplacental transmission [5]. Additionally, male to male sexual
transmission of the virus is also possible through anal sex [6].
2. Epidemiology of ZIKV
The mosquito-borne ZIKV transmission was ﬁrstly reported by
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Brazil in May 2015 [7]. Various samples were collected from patients
suﬀering from febrile rash illnesses, and thus conﬁrmed the presence of
ZIKV. However, the introduction of virus into Brazil was suggested to
occur in 2013 as per phylogenetic and molecular clock analyses [8].
Colombia conﬁrmed the presence of local mosquito-borne ZIKV trans-
mission in October 2015. The transmission was subsequently reported
from much of South America, Central America, the Caribbean, and parts
of North America. Fig. 4 shows the prevalence of the ZIKV in various
countries and territories worldwide.
Autochthonous mosquito-borne ZIKV transmission has been con-
ﬁrmed in 49 countries or territories in the Americas till date [9]. In-
terestingly, Bermuda, Canada, and Uruguay have not reported mos-
quito-borne transmission [10]. A total of 754460 suspected and
laboratory-conﬁrmed autochthonous cases of ZIKV infection had been
reported to the Pan American Health Organization (PAHO) from
countries and territories in the Americas from January 2015 to March
2017 [11]. Brazil (346475 cases; 46%) is known for the highest sus-
pected and conﬁrmed cases, followed by Colombia (107206; 14%), and
Venezuela (62200; 8%). Overall by region, South America accounted
for 70% of reported cases, the Caribbean 21%, Central America 9%, and
North America 1%. The total cases of ZIKV infection increased in the
Americas in February 2016. However, the incidence rate varied at
variable times in diﬀerent countries and sub-regions. In the South
America and Central America region, incidence peaked in February
2016 and January 2016, respectively and subsequently declined [12].
Zika virus transmission will be interrupted in some areas, particu-
larly in small island nations, but the infection is likely to become en-
demic in some countries of Americas [13]. An unusual increment in
congenital microcephaly cases suspected to be associated with ZIKV
infection during pregnancy were reported by the Brazilian Ministry of
Health in late 2015. Twenty four countries and territories in the
Americas had reported 2767 conﬁrmed cases of microcephaly asso-
ciated with ZIKV infection during pregnancy up to March 2017. Four-
teen ZIKV infection cases (12 with travel to Paciﬁc Island countries or
territories and 2 with travel to Africa) were identiﬁed among US tra-
vellers from 2007 to 2014, based on testing performed at the Centres for
Disease Control and Prevention (CDC) [14]. United States and the
District of Columbia reported 4937 cases of laboratory-conﬁrmed ZIKV
disease among returning overseas travellers from January 2015 to April
2017. Overall, 3181 (64%) reported cases were in female travellers. The
most frequently reported travel destinations were countries and terri-
tories in the Caribbean (48%), followed by Central America (16%),
North America (11%), South America (4%), Paciﬁc Islands (< 1%), and
Asia (< 1%). A total of 46 cases of ZIKV disease acquired through
sexual transmission from returning travellers were also reported.
In Asia, occasional cases in residents and travellers and small out-
breaks had been reported in the decades after recognition of ZIKV
transmission in the region during the 1950s [15]. However, improved
awareness and surveillance for ZIKV disease since the outbreak in the
Americas have resulted in increased detection and reporting in the re-
gion. Retrospective testing of samples in Bangladesh, Cambodia, and
Lao People's Democratic Republic identiﬁed previously unrecognized
patients with ZIKV infection from last 5–10 years [16]. In November
2016, Vietnam became the second country in Southeast Asia to report a
case of microcephaly linked with ZIKV [17]. The Ministry of Health
reported the ﬁrst local ZIKV in Singapore in August 2016, and several
small clusters and sporadic cases have been reported into 2017 [18].
3. Zika prevalence in India
The Ministry of Health and Family Welfare-Government of India
(MoHFW) reported three laboratory-conﬁrmed cases of ZIKV in
Bapunagar area, Ahmedabad District, Gujarat, India on May 2017.
The routine laboratory surveillance detected a laboratory-conﬁrmed
case of ZIKV through Reverse transcription polymerase chain reaction
(RT-PCR) test at B.J. Medical College, Ahmedabad, Gujarat, India. The
etiology of this case has been further conﬁrmed through a positive RT-
PCR test and sequencing at the National Institute of Virology (NIV),
Pune, India. Other two cases have then been identiﬁed through the
Acute Febrile Illness (AFI) and the Antenatal clinic (ANC) surveillance.
Case I: A 34-year-old female, delivered a clinically well baby at B.J.
Medical College in Ahmedabad on 9 November 2016. During this
period, she developed a low grade fever after delivery. No history of
fever during pregnancy and no history of travel for the past three
months were reported. A sample from the patient was referred to the
Viral Research and Diagnostic Laboratory (VRDL) at the B.J. Medical
College for dengue testing and thereafter found to be positive for ZIKV.
The sample was re-conﬁrmed as ZIKV positive by RT-PCR and se-
quencing at NIV, Pune, India.
Fig. 1. Structure of ZIKV and its transmission agent.
Fig. 2. Most common symptoms of Zika.
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Case II: During the ANC surveillance between 6 and 12 January
2017, a total of 111 blood samples were collected at B.J. Medical
College. One sample from a 22-year-old pregnant female in her 37th
week of pregnancy has been reported ZIKV positive.
Case III: During the AFI surveillance between 10 and 16 February
2017, a total of 93 blood samples were collected at B.J. Medical
College, Ahmedabad, Gujarat, India. One sample from a 64-year-old
male presenting with febrile illness up to 8 days was found to be ZIKV
positive.
In addition to above mentioned cases, a new case of 27-year-old
male from Krishnagiri district in Tamil Nadu has been reported positive
for the ZIKV infection on July 1, 2017, thereby revealing the ﬁrst case
of Zika from Tamil Nadu. According to the preliminary investigation
reports, no one from his family has travelled to any country where ZIKV
is in circulation. Hence, the causative agent was suggested to be due to
the local transmission. Among 200 suspected cases of the ZIKV tested at
King Institute of Preventive Medicine and Research, Guindy, Chennai,
this was the ﬁrst case that was diagnosed positive for Zika.
In view of the ZIKV prevalence, Indian government is undertaking
signiﬁcant steps as mentioned below.
• Sharing of ‘National Guidelines’ and ‘Action Plan’ on this disease
Fig. 3. Zika virus transmission cycle.
Fig. 4. Prevalence of the ZIKV in various countries and territories.
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with the states to combat an outbreak of ZIKV infection and con-
tainment of prevalence in case of any outbreak.
• Setting up an ‘Inter-Ministerial Task Force’ under the Chairmanship
of Secretary (Health and Family Welfare) together with Secretary
(Bio-Technology), and Secretary (Department of Health Research).
• Displaying information for travellers on ZIKV infection by interna-
tional airports and ports.
• Monitoring of vector control measures by the airport health oﬃcers
along with airport organizations, National Centre for Disease
Control (NCDC), and the National Vector Borne Disease Control
Programme (NVBDCP).
• Tracking of AFI by the Integrated Disease Surveillance Programme
(IDSP).
• Diagnosis of virus by NIV, Pune, India and NCDC, Delhi, India.
Entomological laboratories are conducting ZIKV testing on mosquito
samples.
• Monitoring of microcephaly by the Rashtriya Bal Swasthya
Karyakram (RBSK).
• Finalizing the risk communication materials by the Central Health
Education Bureau, in consultation with the United Nations
Children's Fund (UNICEF).
4. Zika virus prevalence in Mexico
In epidemiological week (EW) 48 of 2015, the Mexico International
Health Regulations (IHR) and National Focal Point (NFP) notiﬁed
PAHO/WHO of the detection of two autochthonous Zika cases, vector-
borne transmission, in the states of Nuevo León and Chiapas. The
Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE) per-
formed the diagnostic tests. The ﬁrst autochthonous Zika case was
conﬁrmed in a resident from Monterrey, the capital of Nuevo León
State.
As of EW 34 of 2017, the Mexico Secretariat of Health has reported
conﬁrmed autochthonous Zika cases in 27 states. As of EW 34, the
highest cumulative incidence rate of cases were reported in the order of
Yutacán (61 cases per 100000 population), Colima (40 cases per
100000), Guerrero (25 cases per 100000), Veracruz (25 cases per
100000), and Quintana Roo (24 cases per 100000).
A signiﬁcant increment in the total counts of conﬁrmed Zika cases
was observed until the peak in EW 39 of 2016. Further, an increased
rate of Zika cases was observed from EW 20 to 26 of 2017. A total of
5065 conﬁrmed cases of ZIKV in pregnant women were reported be-
tween 2015 and 2016. However, Mexico's Secretariat of Health has
reported 602 conﬁrmed cases of ZIKV in pregnant women between EW
1 and EW 34 of the same year (Fig. 5) [19].
The Mexico Secretariat of Health has also reported a total of 1131
cases of Guillain-Barre syndrome (GBS) in EW 30 of 2017, 11 being
conﬁrmed with ZIKV infection. The Mexico Secretariat of Health con-
ﬁrmed the ﬁrst case of congenital syndrome associated with ZIKV in-
fection on February 2017. Mexico has reported a total of 15 conﬁrmed
cases of congenital syndrome associated with ZIKV infection as of EW
30. As of November 2017 there have been 2742 conﬁrmed cases of Zika
across Mexico [20].
The most challenging part of the Zika is that there is no developed
vaccine or any form of treatment to cure the patients, especially the
pregnant women. In 2016, the investigation on the treatment of Zika
has achieved a hallmark after the positive response of vaccine tested on
animal models, and thus, enlightened a new hope for clinical trials
studies in future.
5. Zika virus vaccine: The beginning
There are more than 40 vaccine candidates in preclinical develop-
ment after the declaration of ZIKV a ‘Public Health Emergency of
International Concern’ by WHO. Seven vaccine candidates are being
evaluated in phase 1 clinical trials in the United States, Puerto Rico,
Austria, and India, and 1 candidate has entered phase 2b evaluation in
the United States and endemic sites in the Northern and Southern
hemispheres (Table 1) [21].
In 2016, the Food and Drug Administration (FDA) approved a
vaccine for ZIKV that will undergo clinical trial phases. The vaccine
named GLS-5700 has already shown therapeutic role in mice and
monkey. In fact, it is a DNA vaccine where DNA coded to produce the
protein that surrounds the ZIKV is injected into the skin. GLS-5700 is a
small circular piece of DNA, called a plasmid, which encodes the ZIKV
premembrane and envelope (prM-Env) proteins. The site of the injec-
tion is zapped through electroporation that helps the DNA ﬁnd its way
into cells. The cells then trigger the mechanism of training the immune
system to observe the ZIKV as a foreign invader that needs to be tar-
geted by generating antibodies [22]. GLS-5700 is currently being
evaluated in phase I clinical trials.
The National Institute of Allergy and Infectious Diseases (NIAID) is
also designing DNA Zika vaccine based on its promising results on an-
imals. The pre-clinical data has already shown good immunogenicity,
and thus, the Phase I trial has been started.
In spite of tremendous eﬀect of Zika vaccine in animals, there are
still several years of testing and developmental work ahead before its
commercialization. In fact, Phase I trials do not reveal the eﬀectiveness
of any product, but it can be a positive hallmark to determine whether a
product is safe to administer to people and to estimate the promising
dosage.
The pregnant women and women of child-bearing age would be the
major target populace for a Zika vaccine, indicating a high safety bar.
An eﬀective DNA vaccine would likely satisfy safety concerns. Patients
are supposed to receive 3 doses of either 1 or 2mg of GLS-5700, within
a gap of 1 month. Primary outcomes include changes in laboratory
safety measures and incidence of severe adverse events. Secondary
outcomes are binding antibody titers to Zika Env, neutralizing antibody
response against ZIKV, and T-cell response. The researchers expect to
complete the phase I study successfully and then move into a phase II
trial [23]. Researchers believe one dose of its vaccine should be ade-
quate to protect, but the company will also test a two- and three-dose
regimen [24]. The company has the potentiality to commercialize the
Zika vaccine, though it currently does not have production facilities
that can make the vaccine at commercial level.
Two DNA vaccine candidates (VRC5288 and VRC5283) are cur-
rently being tested by the Vaccine Research Center (VRC), NIAID, and
National Institutes of Health (NIH). Based on the sequence of French
Polynesian and early Brazilian ZIKV isolates, the VRC5288 expresses a
codon-modiﬁed ZIKV/JEV chimeric prM-E. It was designed with the 98
amino acids of the E protein (comprising the transmembrane and stem
domains) from JEV swapped with the corresponding regions from ZIKV
E protein. This vaccine candidate is being evaluated in 80 subjects at 3
sites within the United States. The VRC5283 expresses the full ZIKV
prM-E sequence in a 45-subject phase I clinical trial. Now, the VRC5283
has been moved to phase II clinical trial. Interestingly, both of these
DNA vaccines were found to be immunogenic in mice and NHPs [25].
At present, 2 distinct mRNA vaccine approaches have been applied
to ZIKV. The ﬁrst is based on the use of modiﬁed nucleotides and codon
optimization that increases stability and diminishes detection by in-
tracellular innate immune sensors, thereby resulting in the higher
magnitude and duration of vaccine antigen production [26,27]. Apart
from this, intramuscular administration of 2 doses of mRNA-1325
vaccine was eﬀective in immunocompetent mice treated with IFN-α/β
antibody before ZIKV challenge and immunodeﬁcient mice lacking the
IFN-α/β and IFN-γreceptors (AG129) [28]. Since, whole inactivated
virus vaccines have been widely used for ﬂaviviruses such as Yellow
fever virus (YFV), Japanese encephalitis virus (JEV), and Tick-borne
encephalitis virus (TBEV) [29], hence these vaccines are being pursued
for ZIKV too. Bharat Biotechnologies, Hyderabad, India, began the de-
velopment of a whole-inactivated ZIKV vaccine after the outbreak in
French Polynesia in 2013. This vaccine candidate is now in phase I
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clinical trial [30]. Biomedical Advanced Research and Development
Authority (BARDA) has supported Takeda Pharmaceutical and Sanoﬁ
Pasteur to develop whole-inactivated virus ZIKV vaccines.
In last few decades, a lot of work on DNA vaccines had been done
for diﬀerent infectious or non-infectious diseases, but so far none have
reached to the market, except IMOJEV (for Japanese encephalitis, ap-
proved by regulatory authorities in Australia and Thailand).
6. Other experimental vaccines in pipeline
Larocca et al. [31] reported another DNA vaccine against ZIKV. On
the other hand, a puriﬁed inactivated virus (PIV) vaccine had also been
tested (Table 1). The researchers tested single doses of each vaccine in
mice, which was then challenged with ZIKV from either northeast Brazil
or Puerto Rico. The DNA vaccine described by Larocca et al. [31] is a
plasmid encoding full-length Zika prM-Env proteins from the Brazil
BeH815744 strain, as well as smaller portions of the Env protein. The
researchers also tested the immunogenicity and protective property of a
Zika PIV vaccine derived from the Puerto Rico PRVABC59 strain. Mice
were vaccinated with 50 μg DNA vaccine in saline without adjuvant
intramuscularly or with 1 μg PIV vaccine with 100 μg alum adjuvant,
intramuscularly or subcutaneously. The observations revealed that
vaccine was able to protect mice completely against Zika infection,
suggesting ﬁrst report of complete ZIKV protection in an animal model.
All of the vaccinated animals showed no detectable virus after chal-
lenge with ZIKV derived either from Brazil or Puerto Rico. Most im-
portantly, the protection was achieved even after a single-shot im-
munization, suggesting the generalizability of these achievements. Zika
PIV vaccine is being developed in collaboration with the NIAID, and
that phase I trials have been started at the WRAIR and at NIAID partner
sites.
7. Human vaccine: We have to wait
Results in mice are impressive and ﬁndings also suggest sub-
stantially that the development of a safe and eﬃcacious ZIKV vaccine
will likely be feasible. Most DNA vaccines are known to protect mice,
but DNA vaccines so far do not reproduce their protective immunity in
humans. Therefore, the outcomes here may lead developing the vaccine
to phase I trial, but they will not likely have any direct inﬂuence on the
development of a human vaccine. Researchers suggested that if the prM
protein could be produced as a recombinant protein in lieu of a DNA
vaccine, it might be an appropriate platform for developing human
vaccine [31]. Another critical issue for developing an eﬀective Zika
vaccine is its safety during pregnancy and not inducing GBS. In a nut-
shell, the lack of successful translation of vaccine to humans will lead to
the delay development of Zika vaccine in future for its commerciali-
zation.
8. Strategic plan
The “Zika Strategic Response Plan, Revised for July 2016–December
2017” mainly focuses on the prevention and management of medical
complications caused by ZIKV [32]. It also discusses on integrated
mosquito management, sexual as well as reproductive health
Fig. 5. Conﬁrmed cases of ZIKV infection in pregnant women between EW 1 and EW 34 [19].
Table 1
Zika virus vaccine in clinical development [21].
Vaccine Type Vaccine name Immunogen Phase
Nucleic acid DNA GLS-5700 prME I
Nucleic acid DNA VRC5288 prME I
Nucleic acid DNA VRC5283 prME I and II
Nucleic acid mRNA mRNA-1325 prME I and II
Vector based Vector based MV-Zika prME I
Whole
inactivated
Formalin
inactivated
ZPIV Whole virus I
Whole
inactivated
Formalin
inactivated
Puriﬁed
inactivated ZIKV
Whole virus I
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counselling, and health care. The desideratum aim of this strategy is to
support national governments and communities not only to prevent and
manage the complications but also mitigate the socio-economic con-
sequences of ZIKV infection. The ZIKV strategic plan works on fol-
lowing objectives-
i) Detection – This objective demonstrates the development and im-
plementation of integrated surveillance systems for Zika in order to
reveal up-to-date epidemiological and entomological information.
ii) Prevention – This objective focuses on the prevention of adverse
health outcomes associated with ZIKV infection through integrated
vector management, risk communication, and community engage-
ment. In fact, controlling the spread of ZIKV requires diversiﬁed
approach, concerning with vector control and protecting pregnant
women as well as women of reproductive age from infection. This
approach includes implementing integrated vector management
(IVM), targeting all life stages of the Aedes mosquito: egg, larva/
pupa and the adult, reducing the risk of sexual transmission and
other possible routes of transmission, and engaging and empow-
ering communities, private sectors, etc. in mosquito control and
prevention behaviours.
iii) Care and support – This objective focuses on the strengthen health
and social systems at the national and community levels to provide
appropriate services and support to individuals, families, and
communities infected with ZIKV.
iv) Research – The main target of this objective is to generate data and
evidence required for preventing, detecting, and controlling ZIKV
infection. It aims to develop diagnostic products, vaccines, and
other therapeutics for both ZIKV and its complications.
9. Concluding remarks and future consideration
The evidences showed that ZIKV infection is a global health concern
and became a major issue for mankind. Since there is lack of eﬀective
treatment and human vaccine for Zika at present, proper screening,
monitoring, and precaution need to be implemented worldwide. The
emergence of ZIKV infection suggests that we should be more proactive
focusing on basic aspects of viral structure, immunology, and patho-
genesis relevant to the treatment in future. Despite the success of di-
verse antiviral agents in clinical trial phases, the development of new
human vaccines to protect the global community from future outbreaks
of ZIKV would be a challenging approach. Moreover, awareness and
public health campaign are often required to get rid of this infection.
Most importantly, the early onset of this infection needs to be avoided
by proper management and multidisciplinary eﬀorts.
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